These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38850520)

  • 1. A cost-effectiveness analysis of reduced viral transmission with baloxavir marboxil versus oseltamivir or no treatment for seasonal and pandemic influenza management in the United Kingdom.
    Kommandantvold SA; Lemenuel-Diot A; Skedgel C; Pitman R; Rouse P; Zaraket H; Zhou H; Blanchet Zumofen MH
    Expert Rev Pharmacoecon Outcomes Res; 2024 Oct; 24(8):953-966. PubMed ID: 38850520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Public Health and Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for Influenza Pandemic Control in China: A Cost-Effectiveness Analysis Using a Linked Dynamic Transmission-Economic Evaluation Model.
    Jiang Y; Wen J; Sun J; Shu Y
    Pharmacoeconomics; 2024 Oct; 42(10):1111-1125. PubMed ID: 38958667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States.
    Kommandantvold SA; Chang SC; Surinach A; Yau V; Best JH; Zaraket H; Zhou H; Frimpter J; Blanchet Zumofen MH
    Infect Dis Ther; 2024 Sep; 13(9):2071-2087. PubMed ID: 39150658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of baloxavir and oseltamivir antiviral therapy on the transmission of seasonal influenza in China: A mathematical modeling analysis.
    Jiang Y; Lin YF; Shi S; Chen D; Shu Y
    J Med Virol; 2022 Nov; 94(11):5425-5433. PubMed ID: 35770453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza.
    Huang G; Tian Y; Cui W; Zhang X; Zhao Y; Liu X
    J Chemother; 2024 Jul; 36(4):267-282. PubMed ID: 37767970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection.
    Fukao K; Noshi T; Yamamoto A; Kitano M; Ando Y; Noda T; Baba K; Matsumoto K; Higuchi N; Ikeda M; Shishido T; Naito A
    J Antimicrob Chemother; 2019 Mar; 74(3):654-662. PubMed ID: 30476172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
    Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
    Ison MG; Portsmouth S; Yoshida Y; Shishido T; Mitchener M; Tsuchiya K; Uehara T; Hayden FG
    Lancet Infect Dis; 2020 Oct; 20(10):1204-1214. PubMed ID: 32526195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of baloxavir marboxil compared to laninamivir for the treatment of influenza in Japan.
    Skrzeczek A; Ikeoka H; Hirotsu N; Ansaripour A; Aballéa S; Onishi Y; Hill M; Igarashi A
    J Infect Chemother; 2021 Feb; 27(2):296-305. PubMed ID: 33243614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
    Salvatore M; Laplante JM; Soave R; Orfali N; Plate M; van Besien K; St George K
    Transpl Infect Dis; 2020 Aug; 22(4):e13336. PubMed ID: 32449254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Intra-Familial Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Oseltamivir Using an Influenza Transmission Model and a Health Insurance Claims Database.
    Miyazawa S; Takazono T; Hosogaya N; Yamamoto K; Watanabe H; Fujiwara M; Fujita S; Mukae H
    Clin Infect Dis; 2022 Sep; 75(6):927-935. PubMed ID: 35100617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan.
    Dronova M; Ikeoka H; Itsumura N; Hirotsu N; Ansaripour A; Aballéa S; Onishi Y; Hill M; Igarashi A
    Curr Med Res Opin; 2021 Jul; 37(7):1135-1148. PubMed ID: 33858277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Variants With Reduced Baloxavir Marboxil and Oseltamivir Susceptibility in Children With Influenza A During the 2019-2020 Influenza Season.
    Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Fujisaki S; Hashimoto K; Hosoya M
    J Infect Dis; 2021 Nov; 224(10):1735-1741. PubMed ID: 33837427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
    Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
    Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic analysis of baloxavir marboxil, a novel cap-dependent endonuclease inhibitor, in a murine model of influenza virus infection.
    Ando Y; Noshi T; Sato K; Ishibashi T; Yoshida Y; Hasegawa T; Onishi M; Kitano M; Oka R; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
    J Antimicrob Chemother; 2021 Jan; 76(1):189-198. PubMed ID: 33035324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model.
    Koszalka P; George A; Dhanasekaran V; Hurt AC; Subbarao K
    mBio; 2022 Aug; 13(4):e0105622. PubMed ID: 35938724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
    Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.